The rationale behind cholinergic drug treatment for dementia related to cerebrovascular disease

Journal of the Neurological Sciences

Volumn 203-204, Issue , 2002, Pages 131-136

  Grantham, C ^a,c   Geerts, H ^b  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b In Silico Biosciences   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Alzheimer's disease; Cerebrovascular disease; Cholinergic synapse; Galantamine; Nicotinic acetylcholine receptors; Vascular dementia

Indexed keywords

CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; GALANTAMINE; NICOTINIC RECEPTOR;

ALLOSTERISM; ALZHEIMER DISEASE; BRAIN CORTEX; CEREBROVASCULAR DISEASE; CHOLINERGIC NERVE CELL; CHOLINERGIC SYNAPSE; CHOLINERGIC TRANSMISSION; CLINICAL TRIAL; COGNITIVE DEFECT; COMPETITIVE INHIBITION; CONFERENCE PAPER; DIFFUSE LEWY BODY DISEASE; DOPAMINERGIC SYSTEM; HIPPOCAMPUS; HUMAN; LEARNING; MEMORY; MULTIINFARCT DEMENTIA; NERVE DEGENERATION; PARKINSON DISEASE; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; TREATMENT OUTCOME;

AGED; CEREBROVASCULAR DISORDERS; CHOLINERGIC AGENTS; CLINICAL TRIALS; DEMENTIA, VASCULAR; GALANTAMINE; HUMANS; PARASYMPATHETIC NERVOUS SYSTEM; SYNAPTIC TRANSMISSION;

EID: 0037111123     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(02)00274-5     Document Type: Conference Paper

References (49)

1. Erkinjuntti T. Clinical deficits of Alzheimer's disease with cerebrovascular disease and probable VaD. Int. J. Clin. Pract., Suppl. 120:2001;14-23.
2. Maelicke A. The pharmacological rationale for treating vascular dementia with galantamine (Reminyl). Int. J. Clin. Pract., Suppl. 120:2001;24-28.
3. Rocca W.A., Hofman A., Brayne C., Breteler M.M., Clarke M., Copeland J.R.et al. The prevalence of VaD in Europe: facts and fragments from 1980-1990 studies. EURODEM - Prevalence Research Group. Ann. Neurol. 30:1991;817-824.
4. Lobo A., Launer L.J., Fratiglioni L., Andersen K., Di Carlo A., Breteler M.M.et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurology. 54:2000;S4-S9.
5. Winblad B., Brodaty H., Gauthier S., Morris J.C., Orgogozo J.M., Rockwood K.et al. Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? Int. J. Geriatr. Psychiatry. 16:2001;653-666.
6. Wilkinson D., Truyen L. Prolonged treatment benefits of cholinergic agents in Alzheimer's disease. Poster presented at the 17th World Congress of Neurology, London, UK. 2001.
7. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol. Aging. 18(Suppl. 4):1997;S1-S2.
8. Davis K.L., Mohs R.C., Marin D., Purohit D.P., Perl D.P., Lantz M.et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA. 281:1999;1401-1406.
9. Davies P., Maloney A.J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 2:1976;1403.
10. Whitehouse P.J., Price D.L., Struble R.G., Clark A.W., Coyle J.T., Delon M.R. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science. 215:1982;1237-1239.
11. Bartus R.T., Dean R.L. III, Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science. 217:1982;408-414.
12. Nordberg A., Nilsson-Hakansson L., Adem A., Hardy J., Alafuzoff I., Lai Z.et al. The role of nicotinic receptors in the pathophysiology of Alzheimer's disease. Prog. Brain Res. 79:1989;353-362.
13. Schröder H., Giacobini E., Struble R.G., Zilles K., Maelicke A. Nicotinic cholinoceptive neurons of the frontal cortex are reduced in Alzheimer's disease. Neurobiol. Aging. 12:1991;259-262.
14. Perry E.K., Morris C.M., Court J.A., Cheng A., Fairbairn A.F., McKeith I.G.et al. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience. 64:1995;385-395.
15. Perry E., Martin-Ruiz C., Lee M., Griffiths M., Johnson M., Piggott M.et al. Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur. J. Pharmacol. 393:2000;215-222.
16. McKinney M., Coyle J.T. The potential for muscarinic receptor subtype-specific pharmacotherapy for Alzheimer's disease. Mayo Clin. Proc. 66:1991;1225-1237.
17. Whitehouse P.J., Martino A.M., Antuono P.G., Lowenstein P.R., Coyle J.T., Price D.L.et al. Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res. 371:1986;146-151.
18. Nordberg A., Alafuzoff I., Winblad B. Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia. J. Neurosci. Res. 31:1992;103-111.
19. Nordberg A. PET studies and cholinergic therapy in Alzheimer's disease. Rev. Neurol. (Paris). 155(Suppl. 4):1999;S53-S63.
20. Martin-Ruiz C., Court J., Lee M., Piggott M., Johnson M., Ballard C.et al. Nicotinic receptors in dementia of Alzheimer, Lewy body and vascular types. Acta Neurol. Scand., Suppl. 176:2000;34-41.
21. Nordberg A., Lundqvist H., Hartvig P., Lilja A., Langstrom B. Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains - in vivo assessment using positron emission tomography. Alzheimer Dis. Assoc. Disord. 9:1995;21-27.
22. Vizi E.S., Lendvai B. Modulatory role of presynaptic nicotinic receptors in synaptic and non-synaptic chemical communication in the central nervous system. Brain Res. Rev. 30:1999;219-235.
23. Maelicke A. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 11(Suppl. 1):2000;11-18.
24. Rockwood K., Bowler J., Erkinjuntti T., Hachinski V., Wallin A. Subtypes of vascular dementia. Alzheimer Dis. Assoc. Disord. 13(Suppl. 3):1999;S59-S65.
25. Kalaria R.N., Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis. Assoc. Disord. 13(Suppl. 3):1999;S115-S123.
26. Erkinjuntti T. Cerebrovascular dementia. Pathophysiology, diagnosis and treatment. CNS Drugs. 12:1999;35-48.
27. Saito H., Togashi H., Yoshioka M., Nakamura N., Minami M., Parvez H.et al. Animal models of vascular dementia with emphasis on stroke-prone spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. 22(Suppl. 1):1995;S257-S259.
28. Togashi H., Matsumoto M., Yoshioka M., Hirokami M., Minami M., Saito H. Neurochemical profiles in cerebrospinal fluid of stroke-prone spontaneously hypertensive rats. Neurosci. Lett. 166:1994;117-120.
29. Kimura S., Saito H., Minami M., Togashi H., Nakamura N., Nemoto M.et al. Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats. Toxicology. 153:2000;167-178.
30. Togashi H., Kimura S., Matsumoto M., Yoshioka M., Minami M., Saito H. Cholinergic changes in the hippocampus of stroke-prone spontaneously hypertensive rats. Stroke. 27:1996;520-525.
31. Ferrari R., Frasoldati A., Leo G., Torri C., Zini I., Agnati L.F.et al. Changes in nicotinic acetylcholine receptor subunit mRNAs and nicotinic binding in spontaneously hypertensive stroke prone rats. Neurosci. Lett. 277:1999;169-172.
32. Banerjee C., Nyengaard J.R., Wevers A., de Vos R.A., Jansen Steur E.N., Lindstrom J.et al. Cellular expression of alpha7 nicotinic acetylcholine receptor protein in the temporal cortex in Alzheimer's and Parkinson's disease - a stereological approach. Neurobiol. Dis. 7:2000;666-672.
33. Gottfries C.G., Blennow K., Karlsson I., Wallin A. The neurochemistry of vascular dementia. Dementia. 5:1994;163-167.
34. Wallin A., Blennow K., Gottfries C.G. Neurochemical abnormalities in vascular dementia. Dementia. 1:1989;120-130.
35. Tohgi H., Abe T., Kimura M., Saheki M., Takahashi S. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia. J. Neural. Transm. 103:1996;1211-1220.
36. Feldman H., Gracon S. Alzheimer's disease: symptomatic drugs under development. Gauthier S. Clinical Diagnosis and Management of Alzheimer's disease. 1996;239-259 Martin Dunitz, London.
37. Sarter M. Taking stock of cognition enhancers. Trends Pharmacol. Sci. Rev. 12:1991;456-461.
38. Wonnacott S., Marks M.J. Nicotine: not just for cigarettes anymore. Drug Discov. Today. 4:1999;490-492.
39. Maelicke A., Albuquerque E.X. New approach to drug therapy in Alzheimer's disease. Drug Discov. Today. 1:1996;53-59.
40. Thal L.J., Forrest M., Loft H., Mengel H. for the Lu25-109 Study Group Lu25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Neurology. 54:2000;421-425.
41. Lilienfeld S. Galantamine - a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drugs. 8:2002;159-176.
42. NICE Guidance on the Use of Donepezil, Rivastigmine and Galantamine for the Treatment of Alzheimer's Disease. 2001;National Institute for Clinical Excellence, London.
43. Tariot P. Current status and new developments with galantamine in the treatment of Alzheimer's disease. Exp. Opin. Pharmacother. 2:2001;2027-2049.
44. Samochocki M., Zerlin M., Jostock R., Groot Kormelink P.J., Luyten W.H., Albuquerque E.X.et al. Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR. Acta Neurol. Scand., Suppl. 176:2000;68-73.
45. Maelicke A., Samochocki M., Jostock R., Fehrenbacher A., Ludwig J., Albuquerque E.X.et al. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol. Psychiatry. 49:2001;279-288.
46. Albuquerque E.X., Santos M.D., Alkondon M., Pereira E.F., Maelicke A. Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 15(Suppl. 1):2001;S19-S25.
47. Santos M.D., Alkondon M., Pereira E.F.R., Aracava Y., Eisenberg H.M., Maelicke A.et al. The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol. Pharmacol. 61:2002;1173-1180.
48. Geerts H., Spiros A., Finkel L., Carr R. Nicotinic receptor modulation: advantages to successful Alzheimer's disease therapy. J. Neural. Transm., Suppl. 62:2002;201-214.
49. Erkinjuntti T., Kurz A., Gauthier S., Bullock R., Lilienfeld S., Damaraju V. Galantamine is efficacious in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease. Lancet. 359:2002;1283-1290.